Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone.

Hypertension

Division of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland (Y.M., X.-T.S., A.S., J.A.M., D.H.E.).

Published: July 2022

Background: MR (mineralocorticoid receptor) antagonists are recommended for patients with resistant hypertension even when circulating aldosterone levels are not high. Although aldosterone activates MR to increase epithelial sodium channel (ENaC) activity, glucocorticoids also activate MR but are metabolized by 11βHSD2 (11β-hydroxysteroid dehydrogenase type 2). 11βHSD2 is expressed at increasing levels from distal convoluted tubule (DCT) through collecting duct. Here, we hypothesized that MR maintains ENaC activity in the DCT2 and early connecting tubule in the absence of aldosterone.

Methods: We studied AS (aldosterone synthase)-deficient (AS) mice, which were backcrossed onto the same C57BL6/J strain as kidney-specific MR knockout (KS-MR) mice. KS-MR mice were used to compare MR expression and ENaC localization and cleavage with AS mice.

Results: MR was highly expressed along DCT2 through the cortical collecting duct (CCD), whereas no 11βHSD2 expression was observed along DCT2. MR signal and apical ENaC localization were clearly reduced along both DCT2 and CCD in KS-MR mice but were fully preserved along DCT2 and were partially reduced along CCD in AS mice. Apical ENaC localization and ENaC currents were fully preserved along DCT2 in AS mice and were not increased along CCD after low salt. AS mice exhibited transient Na wasting under low-salt diet, but administration of the MR antagonist eplerenone to AS mice led to hyperkalemia and decreased body weight with higher Na excretion, mimicking the phenotype of MR mice.

Conclusions: Our results provide evidence that MR is activated in the absence of aldosterone along DCT2 and partially CCD, suggesting glucocorticoid binding to MR preserves sodium homeostasis along DCT2 in AS mice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177775PMC
http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19159DOI Listing

Publication Analysis

Top Keywords

ks-mr mice
12
enac localization
12
mice
9
mineralocorticoid receptor
8
receptor antagonists
8
absence aldosterone
8
enac activity
8
collecting duct
8
dct2
8
apical enac
8

Similar Publications

Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone.

Hypertension

July 2022

Division of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland (Y.M., X.-T.S., A.S., J.A.M., D.H.E.).

Background: MR (mineralocorticoid receptor) antagonists are recommended for patients with resistant hypertension even when circulating aldosterone levels are not high. Although aldosterone activates MR to increase epithelial sodium channel (ENaC) activity, glucocorticoids also activate MR but are metabolized by 11βHSD2 (11β-hydroxysteroid dehydrogenase type 2). 11βHSD2 is expressed at increasing levels from distal convoluted tubule (DCT) through collecting duct.

View Article and Find Full Text PDF

Background Angiotensin II stimulates epithelial Na channel (ENaC) by aldosterone-independent mechanism. We now test the effect of angiotensin II on ENaC in the distal convoluted tubule (DCT) and cortical collecting duct (CCD) of wild-type (WT) and kidney-specific mineralocorticoid receptor knockout mice (KS-MR-KO). Methods and Results We used electrophysiological, immunoblotting and renal-clearance methods to examine the effect of angiotensin II on ENaC in KS-MR-KO and wild-type mice.

View Article and Find Full Text PDF

Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.

Cancer Biother Radiopharm

April 1999

Department of Radiation Oncology, University of California, Davis, Medical Center, Sacramento 95817, USA.

L6 is a murine IgG2a monoclonal antibody with panadenocarcinoma reactivity. Chimeric L6 (ChL6), the variable region of murine L6 combined with a human IgG1 constant region, has been used in clinical trials for the delivery of radioimmunotherapy to patients with breast cancer. AIDS-associated Kaposi's sarcoma (KS), a malignancy of vascular endothelium, may be an excellent candidate for systemic radioimmunotherapy because KS is well vascularized and radioresponsive.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!